Hypofractionated intensity-modulated radiotherapy in locally advanced unresectable pancreatic cancer: A pilot study

被引：3

作者：

De Felice, Francesca ^{[1
]}

Benevento, Ilaria ^{[1
]}

Bulzonetti, Nadia ^{[1
]}

Shima, Bianka ^{[1
]}

Rubini, Filippo ^{[1
]}

Marampon, Francesco ^{[1
]}

Musio, Daniela ^{[1
]}

Tombolini, Vincenzo ^{[1
]}

机构：

[1] Sapienza Univ Rome, Policlin Umberto 1, Dept Radiotherapy, Viale Regina Elena 326, I-00161 Rome, Italy

来源：

CURRENT PROBLEMS IN CANCER | 2019年 / 43卷 / 05期

关键词：

Radiotherapy; Hypofractionated; IMRT; Pancreas; Duodenum; STEREOTACTIC BODY RADIOTHERAPY; RADIATION-THERAPY; PLUS RADIOTHERAPY; ADENOCARCINOMA; GEMCITABINE; CARCINOMA; TUMORS;

D O I：

10.1016/j.currproblcancer.2019.04.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To test feasibility and safety of hypofractionated intensity modulated radiotherapy (H-IMRT) in pancreatic adenocarcinoma (PAC) treatment. Methods: Patients with unresectable nonmetastatic PAC were prospectively enrolled on a pilot study. Patients received H-IMRT to gross tumor volume to a total dose of 52 Gy (4 Gy/fraction). Toxicity rates, duodenal dosimetric parameters, and clinical outcomes were evaluated. Results: Ten patients received H-IMRT regimen. Objective tumor response was recorded in all patients but one. Gastrointestinal toxicity was the most common acute side effect and its severity moderately correlated with duodenal maximum dose (rho = 0.46) and percentage of duodenal volume exposed to 5 Gy (rho =0.46). The 1-year overall and disease-free survival were 83.3% and 68.6%, respectively. Conclusion: H-IMRT seems to guarantee a high local control rate without severe toxicity. Its use in unresectable non metastatic PAC needs to be further investigated. (C) 2019 Elsevier Inc. All rights reserved.

引用

页码：495 / 503

页数：9

共 26 条

[1]

[Anonymous], 2017, NATL COMPREHENSIVE C

[2]

[Anonymous], SEER CANC STAT REV 1

[3]

[Anonymous], BRADY LW RAD ONCOLOG

[4] Expanding global access to radiotherapy [J].

Atun, Rifat ;

Jaffray, David A. ;

Barton, Michael B. ;

Bray, Freddie ;

Baumann, Michael ;

Vikram, Bhadrasain ;

Hanna, Timothy P. ;

Knaul, Felicia M. ;

Lievens, Yolande ;

Lui, Tracey Y. M. ;

Milosevic, Michael ;

O'Sullivan, Brian ;

Rodin, Danielle L. ;

Rosenblatt, Eduardo ;

Van Dyk, Jacob ;

Yap, Mei Ling ;

Zubizarreta, Eduardo ;

Gospodarowicz, Mary .

LANCET ONCOLOGY, 2015, 16 (10) :1153-1186

[5] SBRT in pancreatic cancer: What is the therapeutic window? [J].

Brunner, Thomas B. ;

Nestle, Ursula ;

Grosu, Anca-Ligia ;

Partridge, Mike .

RADIOTHERAPY AND ONCOLOGY, 2015, 114 (01) :109-116

[6]

Cancer Therapy Evaluation Program, 2009, COMM TERM CRIT ADV E

[7] Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas [J].

Chang, Daniel T. ;

Schellenberg, Devin ;

Shen, John ;

Kim, Jeff ;

Goodman, Karyn A. ;

Fisher, George A. ;

Ford, James M. ;

Desser, Terry ;

Quon, Andrew ;

Koong, Albert C. .

CANCER, 2009, 115 (03) :665-672

[8] Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study [J].

Comito, Tiziana ;

Cozzi, L. ;

Clerici, E. ;

Franzese, C. ;

Tozzi, A. ;

Iftode, C. ;

Navarria, P. ;

D'Agostino, G. ;

Rimassa, L. ;

Carnaghi, C. ;

Personeni, N. ;

Tronconi, M. C. ;

De Rose, F. ;

Franceschini, D. ;

Ascolese, A. M. ;

Fogliata, A. ;

Tomatis, S. ;

Santoro, A. ;

Zerbi, A. ;

Scorsetti, M. .

TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2017, 16 (03) :295-301

[9]

De Felice F, 2014, ANTICANCER RES, V34, P4673

[10] Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review [J].

de Geus, Susanna W. L. ;

Eskander, Mariam F. ;

Kasumova, Gyulnara G. ;

Ng, Sing Chau ;

Kent, Tara S. ;

Mancias, Joseph D. ;

Callery, Mark P. ;

Mahadevan, Anand ;

Tseng, Jennifer F. .

CANCER, 2017, 123 (21) :4158-4167

← 1 2 3 →